Nearly a fifth of patients exited the survodutide trial due to adverse gastrointestinal events such as nausea, vomiting and diarrhea, Boehringer said.
Source link
About The Author
Zealand Pharma Shares Slide After Boehringer Study Shows Obesity Shot’s Side Effects